PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent

Epigenetic expression in T cell leukaemia

B-lymphoid transcriptional programme as a barrier against malignant transformation in acute lymphoblastic leukaemia

Emerging role of radioembolization for hepatocellular carcinoma

Advanced HCC: New systemic treatment options

Surgical management of pancreatic cancer

Highlights from IGILUC 2019

PARP inhibitors and their side effects in solid tumour therapy

KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases

Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma